Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EPTIFIBATIDE for Percutaneous coronary intervention: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 17 adverse event reports in the FDA FAERS database where EPTIFIBATIDE was used for Percutaneous coronary intervention.

Most Reported Side Effects for EPTIFIBATIDE

Side Effect Reports % Deaths Hosp.
Product use in unapproved indication 61 13.2% 0 1
Thrombocytopenia 58 12.6% 0 24
Drug ineffective 39 8.4% 9 22
Off label use 31 6.7% 1 4
Haemoglobin decreased 30 6.5% 3 15
Haemorrhage 28 6.1% 5 7
Vascular stent thrombosis 19 4.1% 0 16
Condition aggravated 14 3.0% 7 10
Gastrointestinal haemorrhage 14 3.0% 1 9
Haematoma 14 3.0% 4 9
Product use issue 14 3.0% 1 2
Hypotension 13 2.8% 6 8
Pulmonary alveolar haemorrhage 13 2.8% 6 7
Subarachnoid haemorrhage 13 2.8% 3 7
Haemoptysis 12 2.6% 2 7

Other Indications for EPTIFIBATIDE

Antiplatelet therapy (60) Product used for unknown indication (57) Acute myocardial infarction (36) Cerebral artery occlusion (29) Thrombosis (26) Coronary artery thrombosis (18) Myocardial infarction (13) Acute coronary syndrome (12) Thrombosis in device (12) Ischaemic stroke (11)

Other Drugs Used for Percutaneous coronary intervention

PRASUGREL (376) CLOPIDOGREL BISULFATE (356) TICAGRELOR (297) ASPIRIN (227) BIVALIRUDIN (159) CANGRELOR (94) HEPARIN (86) ABCIXIMAB (49) INVESTIGATIONAL PRODUCT (46) IODIXANOL (29)

Related Pages

EPTIFIBATIDE Full Profile All Percutaneous coronary intervention Drugs EPTIFIBATIDE Demographics EPTIFIBATIDE Timeline